Brief: Cantargia Presents Clinical Interim Results At ASCO 2022
27/05/2022 24:38
May 26 (Reuters) - Cantargia AB CANTA.ST :
* CANTARGIA PRESENTS CLINICAL INTERIM RESULTS AT ASCO 2022
HIGHLIGHTING THE POTENTIAL OF NADUNOLIMAB IN COMBINATION WITH
CHECKPOINT INHIBITOR
Source text for Eikon: ID:nPre9nMbza
Further company coverage: CANTA.ST
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cantargia AB
See all newsBrief: Cantargia Publishes Nadunolimab CANFOUR Study Data
Brief: Cantargia Announces Outcome Of Rights Issue, Raising About SEK 75 Mln
Brief: Cantargia Carries Out Rights Issue, Enters Loan Agreement
Brief: Cantargia Q1 Operating Loss Narrows To SEK 36.9 Mln
Brief: Cantargia: Early Results From Phase 1B/2A Nadunolimab Trial In MDS And AML